The COVID-19 Clinical Trial team at the Kwame Nkrumah University of Science and Technology (KNUST), has warned the public against using Cryptolepis Songuinolenta (CS) herbal medicine locally known as Nibima as a treatment drug for persons infected with the virus.
The scientists say the announcement made by the Food and Drugs Authority (FDA), indicated that the herbal medicine has been approved for phase two clinical trials on COVID-19 patients.
According to a statement signed by the KNUST’s Relations Officer, Dr. Daniel Norris Bekoe, the team said there has been misinterpretation of the approval by Ghanaians to mean that CS is the herbal medication for coronavirus.
The statement reminds the public that the study is expected to last for three months and will provide updates accordingly.
The team known as KNC19 consists of clinicians and scientists across faculties at KNUST, Komfo Anokye Teaching Hospital (KATH) and other facilities within the Ghana Health Service and the Centre for Plant Medicine Research at the Mampong Akuapem.
